BACKGROUND: The authors recently reported that the SART2 and SART3 antigens encode tumor epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes (CTLs) established from esophageal carcinoma patients. The current study investigated these antigens to explore a potential molecule for specific immunotherapy for colorectal carcinoma patients. METHODS: The SART2 and SART3 antigens were investigated by Western blotting in colorectal carcinoma cell lines and in cancer tissues. For induction of CTLs, peripheral blood mononuclear cells (PBMCs) of HLA A-24-positive cancer patients were stimulated in vitro with peptides. RESULTS: The 140 kD SART3 antigen was expressed in both the cytosol and nuclear fractions of all six colon carcinoma cell lines, 27 of 41 (65.9%) cytosol fractions, 30 of 41 (73.2%) nuclear fractions of colorectal carcinoma tissue samples, and in 0 of 7 non-tumorous tissues. The 100 kD SART2 antigen was expressed in the cytosol fractions of 2 of 6 colon carcinoma cell lines, 5 of 20 (25%) cytosol fractions of colorectal carcinoma tissue samples, and in 0 of 7 non tumorous tissues. HLA-A24-restricted CTLs cytotoxic to colon carcinoma cells were induced from PBMCs of colon carcinoma patients by stimulation with the two immunogenic peptides of SART3. CONCLUSIONS: The SART3 antigen could be an appropriate target molecule for specific immunotherapy for colorectal carcinoma patients. Copyright 2002 American Cancer Society.
BACKGROUND: The authors recently reported that the SART2 and SART3 antigens encode tumor epitopes recognized by HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes (CTLs) established from esophageal carcinomapatients. The current study investigated these antigens to explore a potential molecule for specific immunotherapy for colorectal carcinomapatients. METHODS: The SART2 and SART3 antigens were investigated by Western blotting in colorectal carcinoma cell lines and in cancer tissues. For induction of CTLs, peripheral blood mononuclear cells (PBMCs) of HLA A-24-positive cancerpatients were stimulated in vitro with peptides. RESULTS: The 140 kD SART3 antigen was expressed in both the cytosol and nuclear fractions of all six colon carcinoma cell lines, 27 of 41 (65.9%) cytosol fractions, 30 of 41 (73.2%) nuclear fractions of colorectal carcinoma tissue samples, and in 0 of 7 non-tumorous tissues. The 100 kD SART2 antigen was expressed in the cytosol fractions of 2 of 6 colon carcinoma cell lines, 5 of 20 (25%) cytosol fractions of colorectal carcinoma tissue samples, and in 0 of 7 non tumorous tissues. HLA-A24-restricted CTLs cytotoxic to colon carcinoma cells were induced from PBMCs of colon carcinomapatients by stimulation with the two immunogenic peptides of SART3. CONCLUSIONS: The SART3 antigen could be an appropriate target molecule for specific immunotherapy for colorectal carcinomapatients. Copyright 2002 American Cancer Society.
Authors: Wendy L Allen; Leanne Stevenson; Vicky M Coyle; Puthen V Jithesh; Irina Proutski; Gail Carson; Michael A Gordon; Heinz-Josef D Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston Journal: Mol Cancer Ther Date: 2011-10-25 Impact factor: 6.261
Authors: Philipp Erben; Darko Gosenca; Martin C Müller; Jelena Reinhard; Joannah Score; Francesco Del Valle; Christoph Walz; Jürgen Mix; Georgia Metzgeroth; Thomas Ernst; Claudia Haferlach; Nicholas C P Cross; Andreas Hochhaus; Andreas Reiter Journal: Haematologica Date: 2010-01-27 Impact factor: 9.941
Authors: Sander Bekeschus; Kristian Wende; Mohamed Mokhtar Hefny; Katrin Rödder; Helena Jablonowski; Anke Schmidt; Thomas von Woedtke; Klaus-Dieter Weltmann; Jan Benedikt Journal: Sci Rep Date: 2017-06-05 Impact factor: 4.379
Authors: Alejandro Athie; Francesco P Marchese; Jovanna González; Teresa Lozano; Ivan Raimondi; Prasanna Kumar Juvvuna; Amaya Abad; Oskar Marin-Bejar; Jacques Serizay; Dannys Martínez; Daniel Ajona; Maria Jose Pajares; Juan Sandoval; Luis M Montuenga; Chandrasekhar Kanduri; Juan J Lasarte; Maite Huarte Journal: J Cell Biol Date: 2020-09-07 Impact factor: 10.539